Crescita Therapeutics Inc.
CTX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 89.98% | 98.22% | 117.82% | 57.05% | -26.55% |
| Total Depreciation and Amortization | 15.59% | 7.76% | 2.50% | -7.20% | -14.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -197.37% | -363.38% | -341.85% | -95.43% | -59.57% |
| Change in Net Operating Assets | -79.29% | -95.49% | -58.45% | -42.34% | 387.27% |
| Cash from Operations | -6.46% | -59.96% | 84.56% | 60.67% | 451.92% |
| Capital Expenditure | 51.20% | 47.56% | 24.86% | -34.85% | -1,505.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 58.25% | 52.11% | 21.54% | -27.37% | -1,446.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.78% | -16.78% | -6.93% | -6.81% | -7.67% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 36.84% | 30.31% | 24.24% | 42.97% | 39.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 12.09% | 10.07% | 9.95% | 20.31% | 17.21% |
| Foreign Exchange rate Adjustments | -92.23% | -118.69% | 378.57% | 65.93% | 369.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.14% | -408.92% | 92.97% | 33.55% | -30.48% |